Zobrazeno 1 - 10 of 382 pro vyhledávání: '"De Savi, C."'
1
Akademický článek
Evaluation of STK17B as a cancer immunotherapy target utilizing highly potent and selective small molecule inhibitors.
Autor: Scheuplein F; Blueprint Medicines Corporation, Cambridge, MA, United States., Renner F; Roche Innovation Center Basel, Basel, Switzerland., Campbell JE; Blueprint Medicines Corporation, Cambridge, MA, United States., Campbell R; Blueprint Medicines Corporation, Cambridge, MA, United States., De Savi C; Blueprint Medicines Corporation, Cambridge, MA, United States., Eckmann J; Roche Innovation Center Munich, Penzberg, Germany., Fischer H; Roche Innovation Center Basel, Basel, Switzerland., Ge J; Blueprint Medicines Corporation, Cambridge, MA, United States., Green L; Roche Innovation Center Basel, Basel, Switzerland., Jakob P; Roche Innovation Center Basel, Basel, Switzerland., Kim JL; Blueprint Medicines Corporation, Cambridge, MA, United States., Kinkema C; Blueprint Medicines Corporation, Cambridge, MA, United States., McGinn K; Blueprint Medicines Corporation, Cambridge, MA, United States., Medina R; Blueprint Medicines Corporation, Cambridge, MA, United States., Müller A; Roche Innovation Center Basel, Basel, Switzerland., Perez N; Blueprint Medicines Corporation, Cambridge, MA, United States., Perola E; Blueprint Medicines Corporation, Cambridge, MA, United States., Timsit Y; Blueprint Medicines Corporation, Cambridge, MA, United States., Traore T; Blueprint Medicines Corporation, Cambridge, MA, United States., Hopfer U; Roche Innovation Center Basel, Basel, Switzerland., Tyanova S; Roche Innovation Center Basel, Basel, Switzerland., Tzouros M; Roche Innovation Center Basel, Basel, Switzerland., Wang R; Blueprint Medicines Corporation, Cambridge, MA, United States., Woessner R; Blueprint Medicines Corporation, Cambridge, MA, United States., Dorsch M; Blueprint Medicines Corporation, Cambridge, MA, United States., Bischoff JR; Roche Innovation Center Basel, Basel, Switzerland.
Publikováno v: Frontiers in immunology [Front Immunol] 2024 Oct 21; Vol. 15, pp. 1411395. Date of Electronic Publication: 2024 Oct 21 (Print Publication: 2024).
Zobrazit plný text záznamu
2
Akademický článek
Discovery of BLU-945, a Reversible, Potent, and Wild-Type-Sparing Next-Generation EGFR Mutant Inhibitor for Treatment-Resistant Non-Small-Cell Lung Cancer.
Autor: Eno MS; Blueprint Medicines, 45 Sidney Street, Cambridge, Massachusetts 02139, United States., Brubaker JD; Blueprint Medicines, 45 Sidney Street, Cambridge, Massachusetts 02139, United States., Campbell JE; Blueprint Medicines, 45 Sidney Street, Cambridge, Massachusetts 02139, United States., De Savi C; Blueprint Medicines, 45 Sidney Street, Cambridge, Massachusetts 02139, United States., Guzi TJ; Blueprint Medicines, 45 Sidney Street, Cambridge, Massachusetts 02139, United States., Williams BD; Blueprint Medicines, 45 Sidney Street, Cambridge, Massachusetts 02139, United States., Wilson D; Blueprint Medicines, 45 Sidney Street, Cambridge, Massachusetts 02139, United States., Wilson K; Blueprint Medicines, 45 Sidney Street, Cambridge, Massachusetts 02139, United States., Brooijmans N; Blueprint Medicines, 45 Sidney Street, Cambridge, Massachusetts 02139, United States., Kim J; Blueprint Medicines, 45 Sidney Street, Cambridge, Massachusetts 02139, United States., Özen A; Blueprint Medicines, 45 Sidney Street, Cambridge, Massachusetts 02139, United States., Perola E; Blueprint Medicines, 45 Sidney Street, Cambridge, Massachusetts 02139, United States., Hsieh J; Blueprint Medicines, 45 Sidney Street, Cambridge, Massachusetts 02139, United States., Brown V; Blueprint Medicines, 45 Sidney Street, Cambridge, Massachusetts 02139, United States., Fetalvero K; Blueprint Medicines, 45 Sidney Street, Cambridge, Massachusetts 02139, United States., Garner A; Blueprint Medicines, 45 Sidney Street, Cambridge, Massachusetts 02139, United States., Zhang Z; Blueprint Medicines, 45 Sidney Street, Cambridge, Massachusetts 02139, United States., Stevison F; Blueprint Medicines, 45 Sidney Street, Cambridge, Massachusetts 02139, United States., Woessner R; Blueprint Medicines, 45 Sidney Street, Cambridge, Massachusetts 02139, United States., Singh J; Blueprint Medicines, 45 Sidney Street, Cambridge, Massachusetts 02139, United States., Timsit Y; Blueprint Medicines, 45 Sidney Street, Cambridge, Massachusetts 02139, United States., Kinkema C; Blueprint Medicines, 45 Sidney Street, Cambridge, Massachusetts 02139, United States., Medendorp C; Blueprint Medicines, 45 Sidney Street, Cambridge, Massachusetts 02139, United States., Lee C; Blueprint Medicines, 45 Sidney Street, Cambridge, Massachusetts 02139, United States., Albayya F; Blueprint Medicines, 45 Sidney Street, Cambridge, Massachusetts 02139, United States., Zalutskaya A; Blueprint Medicines, 45 Sidney Street, Cambridge, Massachusetts 02139, United States., Schalm S; Blueprint Medicines, 45 Sidney Street, Cambridge, Massachusetts 02139, United States., Dineen TA; Blueprint Medicines, 45 Sidney Street, Cambridge, Massachusetts 02139, United States.
Publikováno v: Journal of medicinal chemistry [J Med Chem] 2022 Jul 28; Vol. 65 (14), pp. 9662-9677. Date of Electronic Publication: 2022 Jul 15.
Zobrazit plný text záznamu
3
Akademický článek
Mechanistic Insights into a CDK9 Inhibitor Via Orthogonal Proteomics Methods.
Autor: Hendricks JA; Discovery Sciences, AstraZeneca, Boston, Massachusetts 02451, United States., Beaton N; Biognosys AG, Wagistrasse 21, Schlieren 8952, Switzerland., Chernobrovkin A; Pelago Bioscience AB, Banvaktsvägen 20, Solna 17148, Sweden., Miele E; Discovery Sciences, AstraZeneca, Boston, Massachusetts 02451, United States., Hamza GM; Discovery Sciences, AstraZeneca, Boston, Massachusetts 02451, United States.; Molecular, Cellular and Biomedical Sciences, University of New Hampshire, Durham, New Hampshire 03824, United States., Ricchiuto P; Discovery Sciences, AstraZeneca, Cambridge CB4 0WG, U.K., Tomlinson RC; Discovery Sciences, AstraZeneca, Boston, Massachusetts 02451, United States., Friman T; Pelago Bioscience AB, Banvaktsvägen 20, Solna 17148, Sweden., Borenstain C; Discovery Sciences, AstraZeneca, Boston, Massachusetts 02451, United States., Barlaam B; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K., Hande S; Oncology R&D, Boston, Massachusetts 02451, United States., Lamb ML; Oncology R&D, Boston, Massachusetts 02451, United States., De Savi C; Oncology R&D, Boston, Massachusetts 02451, United States., Davies R; Discovery Sciences, AstraZeneca, Cambridge CB4 0WG, U.K., Main M; Discovery Sciences, AstraZeneca, Cambridge CB4 0WG, U.K., Hellner J; Pelago Bioscience AB, Banvaktsvägen 20, Solna 17148, Sweden., Beeler K; Biognosys AG, Wagistrasse 21, Schlieren 8952, Switzerland., Feng Y; Biognosys AG, Wagistrasse 21, Schlieren 8952, Switzerland., Bruderer R; Biognosys AG, Wagistrasse 21, Schlieren 8952, Switzerland., Reiter L; Biognosys AG, Wagistrasse 21, Schlieren 8952, Switzerland., Molina DM; Pelago Bioscience AB, Banvaktsvägen 20, Solna 17148, Sweden., Castaldi MP; Discovery Sciences, AstraZeneca, Boston, Massachusetts 02451, United States.
Publikováno v: ACS chemical biology [ACS Chem Biol] 2022 Jan 21; Vol. 17 (1), pp. 54-67. Date of Electronic Publication: 2021 Dec 25.
Zobrazit plný text záznamu
4
Akademický článek
Discovery of a Series of 7-Azaindoles as Potent and Highly Selective CDK9 Inhibitors for Transient Target Engagement.
Autor: Barlaam B; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom., De Savi C; Oncology R&D, AstraZeneca, Boston, Massachusetts 02451, United States., Dishington A; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom., Drew L; Oncology R&D, AstraZeneca, Boston, Massachusetts 02451, United States., Ferguson AD; Discovery Sciences, AstraZeneca, Boston, Massachusetts 02451, United States., Ferguson D; Oncology R&D, AstraZeneca, Boston, Massachusetts 02451, United States., Gu C; Oncology R&D, AstraZeneca, Boston, Massachusetts 02451, United States., Hande S; Oncology R&D, AstraZeneca, Boston, Massachusetts 02451, United States., Hassall L; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom., Hawkins J; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom., Hird AW; Oncology R&D, AstraZeneca, Boston, Massachusetts 02451, United States., Holmes J; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom., Lamb ML; Oncology R&D, AstraZeneca, Boston, Massachusetts 02451, United States., Lister AS; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom., McGuire TM; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom., Moore JE; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom., O'Connell N; Discovery Sciences, AstraZeneca, Boston, Massachusetts 02451, United States., Patel A; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom., Pike KG; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom., Sarkar U; Oncology R&D, AstraZeneca, Boston, Massachusetts 02451, United States., Shao W; Oncology R&D, AstraZeneca, Boston, Massachusetts 02451, United States., Stead D; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom., Varnes JG; Oncology R&D, AstraZeneca, Boston, Massachusetts 02451, United States., Vasbinder MM; Oncology R&D, AstraZeneca, Boston, Massachusetts 02451, United States., Wang L; Pharmaron Beijing Co., Ltd., 6 Taihe Road BDA, Beijing 100176, P. R. China., Wu L; Pharmaron Beijing Co., Ltd., 6 Taihe Road BDA, Beijing 100176, P. R. China., Xue L; Pharmaron Beijing Co., Ltd., 6 Taihe Road BDA, Beijing 100176, P. R. China., Yang B; Oncology R&D, AstraZeneca, Boston, Massachusetts 02451, United States., Yao T; Pharmaron Beijing Co., Ltd., 6 Taihe Road BDA, Beijing 100176, P. R. China.
Publikováno v: Journal of medicinal chemistry [J Med Chem] 2021 Oct 28; Vol. 64 (20), pp. 15189-15213. Date of Electronic Publication: 2021 Oct 14.
Zobrazit plný text záznamu
7
Akademický článek
Discovery of AZD4573, a Potent and Selective Inhibitor of CDK9 That Enables Short Duration of Target Engagement for the Treatment of Hematological Malignancies.
Autor: Barlaam B; Oncology R&D, AstraZeneca, Cambridge, CB4 0WG, United Kingdom., Casella R; Advanced Drug Delivery, Pharmaceutical Sciences, R&D, AstraZeneca, Boston, Massachusetts 02451, United States., Cidado J; Oncology R&D, AstraZeneca, Boston, Massachusetts 02451, United States., Cook C; Oncology R&D, AstraZeneca, Macclesfield, SK10 2NA, United Kingdom., De Savi C; Oncology R&D, AstraZeneca, Boston, Massachusetts 02451, United States., Dishington A; Oncology R&D, AstraZeneca, Cambridge, CB4 0WG, United Kingdom., Donald CS; Oncology R&D, AstraZeneca, Cambridge, CB4 0WG, United Kingdom., Drew L; Oncology R&D, AstraZeneca, Boston, Massachusetts 02451, United States., Ferguson AD; Discovery Sciences, AstraZeneca, Boston, Massachusetts 02451, United States., Ferguson D; Oncology R&D, AstraZeneca, Boston, Massachusetts 02451, United States., Glossop S; Oncology R&D, AstraZeneca, Cambridge, CB4 0WG, United Kingdom., Grebe T; Oncology R&D, AstraZeneca, Boston, Massachusetts 02451, United States., Gu C; Oncology R&D, AstraZeneca, Boston, Massachusetts 02451, United States., Hande S; Oncology R&D, AstraZeneca, Boston, Massachusetts 02451, United States., Hawkins J; Oncology R&D, AstraZeneca, Cambridge, CB4 0WG, United Kingdom., Hird AW; Oncology R&D, AstraZeneca, Boston, Massachusetts 02451, United States., Holmes J; Oncology R&D, AstraZeneca, Cambridge, CB4 0WG, United Kingdom., Horstick J; Oncology R&D, AstraZeneca, Boston, Massachusetts 02451, United States., Jiang Y; Pharmaron Beijing Co., Ltd., 6 Taihe Road BDA, Beijing, 100176, P. R. China., Lamb ML; Oncology R&D, AstraZeneca, Boston, Massachusetts 02451, United States., McGuire TM; Oncology R&D, AstraZeneca, Cambridge, CB4 0WG, United Kingdom., Moore JE; Oncology R&D, AstraZeneca, Cambridge, CB4 0WG, United Kingdom., O'Connell N; Discovery Sciences, AstraZeneca, Boston, Massachusetts 02451, United States., Pike A; Oncology R&D, AstraZeneca, Cambridge, CB4 0WG, United Kingdom., Pike KG; Oncology R&D, AstraZeneca, Cambridge, CB4 0WG, United Kingdom., Proia T; Oncology R&D, AstraZeneca, Boston, Massachusetts 02451, United States., Roberts B; Oncology R&D, AstraZeneca, Cambridge, CB4 0WG, United Kingdom., San Martin M; Oncology R&D, AstraZeneca, Boston, Massachusetts 02451, United States., Sarkar U; Oncology R&D, AstraZeneca, Boston, Massachusetts 02451, United States., Shao W; Oncology R&D, AstraZeneca, Boston, Massachusetts 02451, United States., Stead D; Oncology R&D, AstraZeneca, Cambridge, CB4 0WG, United Kingdom., Sumner N; Oncology R&D, AstraZeneca, Cambridge, CB4 0WG, United Kingdom., Thakur K; Oncology R&D, AstraZeneca, Boston, Massachusetts 02451, United States., Vasbinder MM; Oncology R&D, AstraZeneca, Boston, Massachusetts 02451, United States., Varnes JG; Oncology R&D, AstraZeneca, Boston, Massachusetts 02451, United States., Wang J; Advanced Drug Delivery, Pharmaceutical Sciences, R&D, AstraZeneca, Boston, Massachusetts 02451, United States., Wang L; Pharmaron Beijing Co., Ltd., 6 Taihe Road BDA, Beijing, 100176, P. R. China., Wu D; Advanced Drug Delivery, Pharmaceutical Sciences, R&D, AstraZeneca, Boston, Massachusetts 02451, United States., Wu L; Pharmaron Beijing Co., Ltd., 6 Taihe Road BDA, Beijing, 100176, P. R. China., Yang B; Oncology R&D, AstraZeneca, Boston, Massachusetts 02451, United States., Yao T; Pharmaron Beijing Co., Ltd., 6 Taihe Road BDA, Beijing, 100176, P. R. China.
Publikováno v: Journal of medicinal chemistry [J Med Chem] 2020 Dec 24; Vol. 63 (24), pp. 15564-15590. Date of Electronic Publication: 2020 Dec 11.
Zobrazit plný text záznamu
8
Akademický článek
Quest for a COVID-19 Cure by Repurposing Small-Molecule Drugs: Mechanism of Action, Clinical Development, Synthesis at Scale, and Outlook for Supply.
Autor: De Savi C; Kymera Therapeutics, 300 Technology Square, Second Floor, Cambridge, Massachusetts 02139, United States., Hughes DL; Cidara Therapeutics, Inc., 6310 Nancy Ridge Drive, Suite 101, San Diego, California 92121, United States., Kvaerno L; Hypha Discovery Ltd, 154C Brook Drive, Milton Science Park, Abingdon OX14 4SD, United Kingdom.
Publikováno v: Organic process research & development [Org Process Res Dev] 2020 Jun 02; Vol. 24 (6), pp. 940-976. Date of Electronic Publication: 2020 Jun 02 (Print Publication: 2020).
Zobrazit plný text záznamu
9
Akademický článek
Promoting reactive oxygen species accumulation to overcome tyrosine kinase inhibitor resistance in cancer.
Autor: Lin, Wei1,2 (AUTHOR), Wang, Xiaojun1 (AUTHOR), Diao, Mingxin1 (AUTHOR), Wang, Yangwei1 (AUTHOR), Zhao, Rong1 (AUTHOR), Chen, Jiaping3 (AUTHOR), Liao, Yongde1 (AUTHOR) liaoyongde@hust.edu.cn, Long, Qinghong4 (AUTHOR) longqh666@163.com, Meng, Yunchong1 (AUTHOR) 15613523559@163.com
Publikováno v: Cancer Cell International. 7/9/2024, Vol. 24 Issue 1, p1-16. 16p.
Zobrazit plný text záznamu
10
Akademický článek
From Tyrosine Kinases to Tyrosine Phosphatases: New Therapeutic Targets in Cancers and Beyond.
Autor: Zhou, Yu1 (AUTHOR) yuzloveflower@163.com, Yao, Zhimeng1,2 (AUTHOR) crcjnu@163.com, Lin, Yusheng1,3 (AUTHOR) easonlin0423@126.com, Zhang, Hao1,4,5 (AUTHOR) haolabcancercenter@163.com
Publikováno v: Pharmaceutics. Jul2024, Vol. 16 Issue 7, p888. 21p.
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje